« Previous
Next »
Titles
- Healthcare workforce2
- A resource guide for using Medicare’s enrollment race and ethnicity data1
- A risk-based approach to monitoring of clinical investigations questions and answers: guidance for industry1
- A step forward for health care market oversight: Oregon Health Authority’s Health Care Market Oversight Program1
- ACF should improve oversight of head start to better protect children’s safety1
- Abuse and neglect: CMS should strengthen reporting requirements to better protect individuals receiving hospice care : report to the Honorable Charles E. Grassley, United States Senate1
- Action level for inorganic arsenic in apple juice: guidance for industry1
- Acute myeloid leukemia: developing drugs and biological products for treatment : guidance for industry1
- Addressing the direct care workforce shortage: a bipartisan call to action1
- Adjusting for covariates in randomized clinical trials for drugs and biological products: guidance for industry1
- Adverse events in hospitals. A quarter of Medicare patients experienced harm in October 20181
- Adverse events toolkit. Clinical guidance for identifying harm1
- Adverse events toolkit. Medical record review methodology1
- Air travel and communicable diseases: Federal leadership needed to advance research : report to congressional committees1
- Alternative procedures for the manufacture of cold-stored platelets intended for the treatment of active bleeding when conventional platelets are not available or their use is not practical: guidance for industry1
- An estimated 91 percent of nursing home staff nationwide received the required COVID-19 vaccine doses, and an estimated 56 percent of staff nationwide received a booster dose1
- Animal use in research: NIH should strengthen oversight of projects it funds at foreign facilities : report to congressional requesters1
- Annual status report information and other submissions for postmarketing requirements and commitments: using forms FDA 3988 and FDA 3989 : guidance for industry1
- Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Antimicrobial susceptibility test (AST) system devices: updating breakpoints in device labeling : guidance for industry and Food and Drug Administration staff1